|Review of various commercial development efforts, packed with surface info. Good starting point.|
Love to see the totality of data behind this..... "The cell-based ligand screening involved approximately 80 phytocannabinoids, with the initial screen resulting in the identification of several hits that were effective in preventing the activation of the cells by transforming growth factor-beta, or TGF-beta."
Something like this pops out, and you wonder if cognitive disorder is just a shot in the dark or ????. In context, one might go.... "yeah, neuropathic pain, but.... huh?" Different context?
"Cleveland Clinic spinout Neurotherapia Inc. is seeking to move NTRX-07, a CB2 agonist, into the clinic to treat cognitive disorder and neuropathic pain"